ClinicalTrials.gg
Status unknownNCT04629287Updated Nov 19, 2020

Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection

A Phase 1 interventional study of KPCXM18 and Placebo in Healthy, sponsored by Kunming Pharmaceuticals, Inc.. Status unknown. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-19.

Sponsored by Kunming Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

to assess the safety,Tolerability, and pharmacokinetic of KPCXM18 for injection in healthy subjects

Read the detailed description

To explore the safety, tolerance and pharmacokinetic of KPCXM18 for injection in healthy subjects by intravenous administration of different doses in single and multiple administration safety, tolerance and pharmacokinetic tests, and to obtain the safe dose range of the test drugs, thus providing dose design basis for phase II clinical trials.

02

Conditions studied

  • Healthy

Browse trials for

Keywords

  • stroke
03

In context

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

This study's planned enrollment of 102 is above the median of 48 across 6,037 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between 19 and 26 kg/m2;male body weight not less than 50.0kg,female body weight not less than 45.0kg ;
  2. General physical examination and physical and chemical examination are qualified.
  3. Volunteers can communicate well with the investigator, understand and comply with the relevant requirements of the study, understand and sign the ;

Exclusion criteria

Exclusion Criteria:

  1. Any condition that might interfere with the procedures or tests in this study;
  2. Drinking(more than 14 units of alcohol per week) in 6 months ;
  3. Smoking (more than 10 cigarettes per day or equal amount of tobacco) within 3 months (90 days) ;
  4. Have special requirements on diet, or cannot follow a unified diet ;
  5. Used a clinical trial drug within 3 months prior to administration ;
  6. Positive blood pregnancy test of female subjects ;
  7. Subjects may not be able to complete the study for other reasons or the investigator considers that they should not be included .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    KPCXM18 for injection

    KPCXM18 ,freeze-dried powder,single and multiple ascending doses, Intravenous route

    Drug: KPCXM18 · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route

    Drug: KPCXM18 · Drug: Placebo

Interventions

  • DrugKPCXM18

    KPCXM18,blind,freeze-dried powder,ascending doses,Intravenous route

  • DrugPlacebo

    Placebo,blind,freeze-dried powder,ascending doses,Intravenous route

06

What researchers measure

Primary outcomes

  1. Number of subjects with abnormal vital signs

    To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal vital signs

    Time frame: through study completion, an average of 2 week

  2. Number of subjects with abnormal laboratory

    To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal laboratory

    Time frame: through study completion, an average of 2 week

  3. Number of subjects with abnormal physical examination

    To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal physical examination

    Time frame: through study completion, an average of 2 week

  4. Number of subjects with abnormal electrocardiogram

    To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal electrocardiogram

    Time frame: through study completion, an average of 2 week

  5. Number of subjects with adverse events

    To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal adverse events

    Time frame: through study completion, an average of 2 week

Secondary outcomes

  1. Pharmacokinetics of KPCXM18 in plasma: Cmax

    To characterize the pharmacokinetic parameters:Cmax of KPCXM18 after the first day administer

    Time frame: Time Frame: Between Day 1 to 7 days

  2. Pharmacokinetics of KPCXM18 in plasma: Tmax

    To characterize the pharmacokinetic parameters:Tmax of KPCXM18 after the first day administer

    Time frame: Time Frame: Between Day 1 to 7 days

  3. Pharmacokinetics of KPCXM18 in plasma: AUC0-∞

    To characterize the pharmacokinetic parameters: AUC0-∞ of KPCXM18 after the first day administer

    Time frame: Time Frame: Between Day 1 to 7 days

  4. Pharmacokinetics of KPCXM18 in plasma:t1/2

    To characterize the pharmacokinetic parameters: t1/2 of KPCXM18 after the

    Time frame: Time Frame: Between Day 1 to 7 days

  5. Pharmacokinetics of KPCXM18 in plasma: Cmax,ss

    To characterize the pharmacokinetic parameters:Cmax,ss of KPCXM18 after the 14th day administer

    Time frame: Time Frame: Between Day 1 to 14 days

  6. Pharmacokinetics of KPCXM18 in plasma: AUC0-∞,ss

    To characterize the pharmacokinetic parameters:AUC0-∞,ss of KPCXM18 after the 14th day administer

    Time frame: Time Frame: Between Day 1 to 14 days

  7. Pharmacokinetics of KPCXM18 in plasma: Tmax,ss

    To characterize the pharmacokinetic parameters:Tmax,ss of KPCXM18 after the 14th day administer

    Time frame: Time Frame: Between Day 1 to 14 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2020; primary completion for Dec 2021, 13 months later.

Of 26 industry-sponsored phase 1 interventional studies under Stroke, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 13 months is above that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Nov 16, 2020
StartEst.
Nov 2020
Primary completionEst.
Dec 2021
CompletionEst.
Feb 2022
Last update
Nov 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04629287
Lead sponsor
Kunming Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
Nov 2020 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Feb 2022 (estimated)
Last update
Nov 19, 2020

Study contacts

duo gao, ph.D
Contact
duo.gao@kpc.com.cn
0871-68319868 ext. 3502
yuhong huang, Prof.
principal investigator · Second Affiliated Hospital of Tianjin University of TCM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion